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Abstract
Feto-acinar pancreatic protein (FAPP) characterized by
mAbJ28 reactivity is a specific component associated
with ontogenesis and behaves as an oncodevelop-
ment-associated antigen. We attempted to determine
whether pancreatic tumoral SOJ-6 cells are expressed
at their surface FAPP antigens and to examine if spe-
cific antibodies directed against these FAPP epitopes
could decrease the growth of pancreatic tumors in
a mice model. For this purpose, we used speci-
fic antibodies against either the whole FAPP, the
O-glycosylated C-terminal domain, or the N-terminal
domain of the protein. Our results indicate that SOJ-6
cells expressed at their surface a 32-kDa peptide
corresponding to the C-terminal domain of the FAPP.
Furthermore, we show, by using endoproteinase Lys-C
or geldanamycin, a drug able to impair the FAPP
secretion, that this 32-kDa peptide expressed on the
SOJ-6 cell surface comes from the degradation of the
FAPP. Finally, an in vivo prospective study using a
preventative tumor model in nude mice indicates that
targeting this peptide by the use of mAb16D10 inhibits
the growth of SOJ-6 xenografts. The specificity of
mAb16D10 for pancreatic tumors and the possibility to
obtain recombinant structures of mucin-like peptides
recognized by mAb16D10 and mAbJ28 are promising
tools in immunologic approaches to cure pancreatic
cancers.
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Introduction
The bile salt–dependent lipase (BSDL; EC 3.1.1.13) is
found in the pancreatic secretions of all species examined
up to now, from fish to humans [1]. This enzyme plays
an essential role in the intestinal processing of cholesterol
[2–4]. During its transport from the endoplasmic reticulum
to the trans-Golgi network, BSDL is associated with intracel-
lular membranes by means of a complex that involves the
glucose-related protein of 94 kDa or Grp94 [5,6]. This chaper-
one controls the late folding steps and the sorting of the active
enzyme toward secretion [7]. Once in the trans-Golgi network
and after completion of glycosylation [8,9], the complex is
released from membranes upon the phosphorylation of the
Thr residue at position 340 [10] by a protein kinase CKII
[11,12]. Once released from intracellular membranes, BSDL
enters the secretion route.
The feto-acinar pancreatic protein (FAPP) is a specific
component of acinar cells of the human pancreas, which is
associated with the ontogenesis and development of the gland
[13]. FAPP has been characterized using the patented mono-
clonal antibody mAbJ28 [14]. Maximum synthesis of FAPP,
determined as the emergence of the J28 epitope, occurs when
acinar cell proliferation is maximal between 20 and 22 weeks
gestation; it then declines to parturition [15]. Thereafter, FAPP,
defined by the expression of the J28 epitope, behaves as an
oncodevelopment-associated antigen [13]. FAPP (a 100- to
120-kDa protein) presents many homologies with BSDL (a 100-
kDa protein) [16], and its cloning from human pancreatic
tumoral cells [17] indicates that the N-terminal domain encoded
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by exons 1 to 10 is identical to that of BSDL. However, the
sequence corresponding to exon 11, which encodes for 16
identical repeated sequences (C-terminal domain) of BSDL,
is deleted by 330 bp and encodes only six of these repeated
sequences on FAPP. Albeit, this latter protein is poorly
secreted by pancreatic tumoral cells [13,18,19]; its low
rate of secretion might not result from inherent properties
of the protein, which is a priori normally N-glycosylated and
O-glycosylated [16,17] and phosphorylated [10]. The reten-
tion of FAPP in human pancreatic tumoral SOJ-6 cells could
result from a defect of Rab6 cycling due to the expression
of a defective Rab GDIb [20]. The localization of FAPP in
tumoral cells indicates that the protein, which is mainly mem-
brane-associated like its normal counterpart BSDL, distrib-
utes within the endoplasmic reticulum and the Golgi [18].
Such retention of the protein associated with modifications in
glycosyltransferase expression due to pancreatic neoplastic
processes [21] could be responsible for the formation on
the C-terminal mucin-like domain of FAPP [22] of the J28
epitope that requires the core 2 b(1–6) N-acetylglucosami-
nyltransferase and the a(1 – 3/4) fucosyltransferase
[23,24]—two glycosyltransferases normally located within
the late Golgi compartment [25].
It is likely that the retained enzyme cannot indefinitely
accumulate within tumor cells and should be degraded fol-
lowing the same way as aberrant BSDL molecules [26]. The
question is how to determine what could be the future of
degradation products, in part the C-terminal domain that car-
ries out oncofetal epitopes. Antigenic peptides issued from
FAPP degradation could be presented at the surface of
tumoral cells. Supporting this is the report that 125I mAbJ28
administrated to hamsters treated with nitrosamines to in-
duce pancreatic cancer accumulated at the level of the
pancreas, and that the maximal accumulation is associated
with pleomorphic alterations of the acinar tissues at pretu-
moral stage [27]. This suggests that peptides or proteins that
carry out the J28 epitope can be presented at the surface
of tumoral cells. In the present study, we effectively de-
scribed that a 32-kDa peptide issued from the FAPP de-
gradation is presented at the surface of human pancreatic
SOJ-6 cells. This peptide is specifically recognized by
mAbJ28 and mAb16D10, two monoclonal antibodies direct-
ed against the O-glycosylated C-terminal domain of FAPP.
The specificity of mAb16D10 allowed us to investigate its
efficacy in pancreatic cancer models. In a prospective study,
we showed that the growth of xenografted SOJ-6 cells in




RPMI 1640, Ham F12, Opti-MEM media, glutamine,
penicillin, streptomycin, trypsin–EDTA, fungizone, zeocin,
and fetal calf serum (FCS) were purchased from Invitrogen
(Cergy-Pontoise, France). Paraformaldehyde was from
Fluka (Buchs, Switzerland). Bovine serum albumin (BSA),
streptavidin–agarose, geldanamycin, and cell dissociation
solution were obtained from Sigma (St. Louis, MO). Com-
plete EDTA-free (a mix of protease inhibitors) and endopro-
teinase Lys-C were purchased from Roche Diagnostic
(Meylan, France). Isoflow buffer was purchased from Coulter
(Hialeah, FL). Sulfo-NHS-LC-biotin was from PerbioScience
(Helsiborg, Sweden).
Antibodies
Polyclonal antibodies raised against purified human
BSDL were obtained in our laboratory and isolated by affinity
chromatography on protein A Sepharose [28]. These anti-
bodies, referred to as pAbL64, were able to react with non-
glycosylated and glycosylated domains of BSDL obtained by
in vitro translation using human pancreatic mRNA and rabbit
reticulocytes [17]. The patented monoclonal antibody
(mAbJ28) specific for the fucosylated J28 glycotope carried
by repeated C-terminal sequences of the oncofetal glycoiso-
form of BSDL (i.e., FAPP) was a generous gift from Dr. M. J.
Escribano (INSERM, Marseilles, France). The mouse mo-
noclonal antibody (mAb16D10) also directed against
O-glycosylated repeated C-terminal sequences of FAPP
(unpublished observation) and a polyclonal rabbit antibody
(pAbAntipeptide) directed against a synthetic peptide of
FAPP located within the N-terminal domain of the protein
from Ser326 to Glu350 [29] were obtained from our labora-
tory. All the details concerning the specificity of these anti-
bodies are given in Table 1. Polyclonal antibodies to the
glucose transporter Glut-1 came from Chemicon Internation-
al (Temecula, CA). Fluorescein isothiocyanate (FITC)–con-
jugated anti–mouse goat IgG, FITC-conjugated anti–mouse
goat IgM, FITC-conjugated anti–rabbit goat IgG, alkaline
Table 1. Antibody Specificity.
Antibody Name Specificity Particularity
pAbL64 BSDL and FAPP Obtained by rabbit immunization with a mix of BSDL and FAPP [28]
Binds to nonglycosylated and glycosylated BSDL and FAPP [16]
pAbAntipeptide BSDL and FAPP Obtained by immunization of rabbits with a peptide sequence from Leu348
to Ser371 located in the N-terminal domain of BSDL and FAPP
mAbJ28 FAPP Binds to a fucosylated glycotope located in the C-terminal domain of FAPP [23]
Binds to fetal and tumoral pancreatic human tissues [14,15]
Does not recognize other fetal, normal, or tumoral human tissues [14,15]
mAb16D10 FAPP Binds to the C-terminal domain of FAPP (unpublished observation)
Binds to human pancreatic tumoral tissue (unpublished observation)
Does not recognize human pancreatic normal tissues (unpublished observation)
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phosphatase–conjugated anti–mouse goat IgG, alkaline
phosphate–conjugated anti–rat goat IgG, and alkaline phos-
phatase–conjugated anti–rabbit goat IgG were from Sigma.
Peroxidase-conjugated anti–mouse and anti– rabbit goat
IgG were from Roche Diagnostic.
Cell Culture
The SOJ-6 [30] cell line that constitutively expresses
FAPP [17] was kindly provided by Dr. M. J. Escribano.
SOJ-6 cells were grown inRPMI 1640medium supplemented
with 10% FCS, glutamine (2 mM), penicillin (100 U/ml),
streptomycin (100 mg/ml), and fungizone (0.1%). The CHO-
C2-F3 cell line, issued from the CHO-K1 cell line (ATCC,
Rockville, MD), was transfected with cDNA encoding glyco-
syltransferases, core 2 b(1–6)N-acetylglucosaminyltransfer-
ase, and a(1–3/4) fucosyltransferase [23]. CHO-C2-F3 cells
were grown in Ham F12 medium supplemented with 10%
FCS, 2 mM glutamine, penicillin (100 U/ml), streptomycin
(100 mg/ml), fungizone (0.1%), geneticin (500 mg/ml), and
hygromycin (200 mg/ml). Cells were kept at 37jC in an humi-
dified atmosphere of 95% air and 5% CO2.
Preparation of Cell Extracts
Cells were washed in PBS (10 mM sodium phosphate
buffer, pH 7.4, 150 mM NaCl), harvested with a rubber
policeman, washed once again in PBS, and pelleted by
centrifugation. Pellets were washed twice with PBS and
lysed for 30 minutes at 4jC in 100 ml of buffer (pH = 7.5;
10 mM Tris–HCl, 150 mM NaCl, 1% Triton X-100, and
complete). Cell debris and insoluble materials were eliminat-
ed by centrifugation (14,000g, 30 minutes, 4jC) and soluble
fractions were either immediately assayed or stored at
20jC until use.
Construction of Plasmids
The cDNA encoding the C-terminal tandem repeated
sequence of FAPP (Cter-cDNA) was obtained by reverse
transcription of mRNA extracted from SOJ-6 cells. The
cDNA() pool was amplified by performing a polymerase
chain reaction (PCR) using a pair of primers designed to
cover this sequence [17] from nucleotide 1089 (Phe364) to
nucleotide 1839 (termination codon) (Cter FAPP-5; 5V-
CGTCTAaagcttTTTGATGTCTACACCGAGTCC and Cter
FAPP-3; 5V-TTTCGTgaattcACGCTAAAACCTAATGACTG-
CAGGCATCTG) and using the GC-rich PCR kit from Clon-
tech (Palo Alto, CA). These two primers include HindIII and
EcoRI overhangs (lower case letters) for the ligation into the
pSecTag vector (Invitrogen), which carries the gene for
resistance to zeocin. Bases were randomly added in 5V of
these primers to allow efficient restrictive cleavage of PCR
fragments. To eliminate the myc epitope and the sequence
coding the six histidine residues in the 3V-end of the multi-
cloning site of the pSecTag vector, a stop codon was
introduced in the primer hybridizing with the 3V-end of the
Cter-cDNA. The DNA was amplified using a 35-reaction
cycle program as follows: denaturation (94jC, 1 minute),
annealing (52jC, 1 minute), and extension (68jC, 4 min-
utes). The reaction was terminated by an incubation at 68jC
for 10 minutes. PCR fragments were analyzed on 1% aga-
rose gel. After purification using the nucleospin extract
(Macherey-Nagel, Hoerdt, France), transcripts were sub-
cloned into pCR2.1 TOPO vector (Invitrogen) and sequenc-
ed usingM13 forward and reverse primers. Once sequenced,
the transcript referred to as Cter-cDNA was excised by
HindIII and EcoRI digestion and ligated into the pSecTag
expression/secretion vector to give the pSecCterFAPP.
PCR experiments were performed with a Gene AmpPCR
System 2400 (PE Applied Biosystem, Roissy, France).
Transfection
Stable transfection of CHO-C2-F3 cells [24] was per-
formed with pSecCterFAPP and using the Lipofectamine-
mediated transfection procedure according to the manufac-
turer (Invitrogen). CHO-C2-F3 cells were grown as described
above. Semiconfluent cells were typically transfected with
1 mg of pSecCterFAPP plasmid. Antibiotic-resistant cells
were selected using several medium exchanges with Ham
F12 containing 10% FCS, geneticin (500 mg/ml), hygromycin
(200 mg/ml), and zeocin (500 mg/ml) during a time period of at
least 4 weeks. Zeocin-resistant clones secreting the recom-
binant C-terminal peptide of FAPP (CterFAPP) were isolated
using cloning cylinders and visualized by fluorescence mi-
croscopy using pAbL64.
Fluorescence Microscopy
Cells grown to 80% confluence on microscope coverslips
were washed three times with PBS buffer and fixed with 3%
(vol/vol) paraformaldehyde for 20 minutes. The excess of
paraformaldehyde was eliminated by washing the slides in
1 M glycine (pH 8.5). Between each step, cells were exhaus-
tively rinsed with PBS. Then cells were treated for immuno-
fluorescence as already described [17] using adequate
primary antibodies and conjugates.
Flow Cytometry
Detection of antigens at the surface of SOJ-6 cells was
carried out by indirect fluorescence under the following
conditions: cells were released from culture plates by treat-
ment with a nonenzymatic cell dissociation solution for 15
minutes at 37jC. All subsequent steps were carried out at
4jC. The cells were washed with PBS, fixed with 2%
paraformaldehyde in PBS for 10 minutes, and extensively
washed with 1% BSA in PBS. Antigens were exposed for
1 hour to specific antibodies, washed with PBS, and finally
incubated for 30 minutes with adequate FITC-labeled sec-
ondary antibodies. Cells were then washed, resuspended
in Isoflow buffer, and analyzed on an EPICS Profile II flow
cytometer (Coulter). Detection of antigens located intracel-
lularly in SOJ-6 cells was carried out by indirect fluorescence
with modified conditions: the cells were released from culture
plates by treatment with trypsin–EDTA solution for 5 min-
utes. After fixation with 2% paraformaldehyde, cells were
permeabilized with 0.05% saponin in PBS for 15 minutes.
Then the protocol was the same as described above.
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Polyacrylamide Gel Electrophoresis and Western Blot
Analysis
Gel electrophoreses (sodium dodecyl sulfate polyacryl-
amide gel electrophoresis, or SDS-PAGE) were performed
on slab gels of polyacrylamide (10% acrylamide) and 0.1%
sodium dodecyl sulfate [31]. Proteins were electrophoreti-
cally transferred onto a nitrocellulose membrane [32] in 0.2 M
Tris–HCl (pH 9.2) buffer (10% methanol) at 0.3 mA/cm2
overnight in a cold room. Transfer was verified by staining
membranes with Ponceau red and replicas were developed
using polyclonal antibodies to pancreatic BSDL (pAbL64)
and the glucose transporter Glut-1, or the monoclonal anti-
body specific for the J28 glycotope (mAbJ28) or mAb16D10
or pAbAntipeptide. Quantification was performed using the
NIH-Image program (developed at the U.S. National Insti-
tutes of Health, http://rsb.info.nih.gov/nih-image/).
Sequence Determination
The SDS-PAGE gel area corresponding to the pAbL64-
reactive material was excised and electroeluted (Biotrap
device; Schleicher and Schuell, Dassel, Germany). After
dialysis/concentration (Centricon; Millipore, Billerica, MA),
the electroeluted material was sequenced (IBSM-CNRS,
Marseille, France).
Biotinylation and Streptavidin Precipitation of Cell Surface
Proteins
The protocol is based on a method developed by Altin and
Pagler [33] and modified in our laboratory. The SOJ-6 cells
were washed three times with PBS, then were released from
culture plates by treatment with a nonenzymatic cell disso-
ciation solution for 15 minutes at 37jC. The cells were
suspended at a concentration of 25  106 cells/ml in ice-
cold PBS (pH 8.0) and 0.5 mg of sulfo-NHS-LC biotin was
added per milliliter of reaction volume including complete
EDTA-free mix to avoid degradation of proteins. The mixture
was incubated at 4jC for 2 to 3 hours. Then the cells were
washed three times with ice-cold PBS (pH 8.0) to remove the
remaining biotinylation reagent. After centrifugation, the cell
pellet was resuspended in an adequate volume of ice-cold
PBS, sonicated twice for 15 seconds, and, after a 30-minute
centrifugation at 13,000g, the supernatant containing cell
surface–biotinylated proteins was saved. Biotinylated pro-
teins (300 mg) were loaded on streptavidin–agarose beads
(150 ml) and were incubated overnight at 4jC under agitation.
Beads were exhaustively washed with PBS, then complexes
formed of biotinylated proteins bound to streptavidin–aga-
rose were dissociated by 0.1 M acetic acid (pH 2.0) for
30 minutes at 37jC, and centrifuged to collect the biotin-
ylated proteins that were found in the supernatant. Alterna-
tively biotinylated surface peptides were purified by
steptavidin precipitation, then immunoprecipitated with
pAbL64 or mAbJ28 using the Seize primary immunoprecip-
itation kit (PerbioScience). Immunoprecipitated and biotin-
ylated peptides were separated on SDS-PAGE and
electrotransferred onto nitrocellulose membranes. Mem-
branes were probed with adequate primary and secondary
antibodies to detect immunoprecipitated biotinylated pepti-
des using Supersignal West Pico (PerbioScience).
Protein Purification, Protein Concentration, and Activity
Determinations
BSDL was purified from normal human pancreatic juice
[1]. Proteins were quantified using the bicinchoninic acid
assay from PerbioScience using BSA as standard. FAPP
activity was determined on 4-nitrophenyl hexanoate in the
presence of 4 mM sodium taurocholate as specific activator
of the enzyme [8].
Enzymatic Degradation Using Endoproteinase Lys-C
Enzymatic degradation was performed in 25 mM Tris–
HCl, 1 mM EDTA pH 8.5 buffer. The recombinant C-terminal
peptide of FAPP (120 mg), which arborated the J28 glyco-
tope, pure human pancreatic BSDL (120 mg), and SOJ-6 cell
culture supernatant containing FAPP (120 mg), was specifi-
cally degraded by addition of endoproteinase Lys-C (2% by
weight) at 37jC overnight. The reaction was stopped by
freezing, and the reaction medium was then lyophilized and
suspended in an adequate volume of Laemmli’s buffer [31]
before separation on SDS-PAGE and analysis by Western
blot analysis.
Animals and Tumor Induction
Female NMRI Nu/Nu mice (6 weeks old) were purchased
from Janvier (Le Genest-St-Isle, France) and were kept
under pathogen-free conditions. All tissue removal proce-
dures and animal care were carried out according to ac-
creditation Nb 04333 given by the French Ministe`re de
l’Agriculture. SOJ-6 human pancreatic tumoral cells were
cultured to 90% confluence, washed twice with cold PBS,
and harvested with the cell dissociation solution. The cells
were pelleted and washed three times with PBS and kept on
ice until injection. The animals were anesthesized with Foren
inhalations (Abbott Laboratories, Pasadena, CA) and the
tumor cell suspension (2  106 cells in 150 l of PBS) was
inoculated subcutaneously in the right flank of each animal.
Two groups of five mice each were constituted. One day
before (day 1) tumoral cell inoculation (day 0), the control
group received an intraperitoneal injection of 150 l of PBS
(vehicle), whereas the assay group received 0.5 mg of
mAb16D10 in 150 ml of PBS. Vehicle buffer or mAb16D10
was then injected in animals at days +1, +3, +6, +8, and + 10.
When the tumor became palpable, measurements in two
dimensions with Vernier calipers were performed once a
week and the volume of tumors was calculated according to
the formula of ellipsoid volume: (P/6)(ab2), where a is the
largest and b is the smallest diameter of the tumor.
Results
Antibodies to FAPP Recognize 28- to 32-kDa Peptides in
SOJ-6 Cell Lysates
It has been previously shown that FAPP but not BDSL
was expressed by SOJ-6 cells [18]. The first goal of the
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present study was to determine whether the entire FAPP or a
peptide derived from the FAPP was expressed at the surface
of the SOJ-6 cell line. To demonstrate this proposal, we first
attempted to detect degradation products of FAPP within
SOJ-6 cell lysates by using an antibody directed against
FAPP (pAbL64). Human pancreatic SOJ-6 tumoral cells
were cultured in Opti-MEM medium in the absence of FCS
for 24 hours. Cells were harvested, lysed in the presence of
Triton X-100, and centrifuged to isolate solubilized material.
Proteins present in the serum-free culture medium and the
soluble fraction of cell lysate were separated on SDS-PAGE,
electrotransferred onto nitrocellulose membranes, and
probed with the polyclonal antibody pAbL64 [16] (Table 1).
The results indicated that a protein associated with an Mr
of around 120 kDa corresponding to the FAPP [18] was
present in the cell-free culture medium of SOJ-6 cells
(Figure 1, lane 1). Interestingly, in cell lysate, pAbL64mainly
recognizes peptides around 30 kDa (lane 2, arrows), which
could be degradation products of FAPP. The 120-kDa pro-
tein is also present in cell lysates but in a very low amount
as a result of degradation, or because FAPP in SOJ-6 cells
is mainly associated with insoluble materials [17].
Antibodies to FAPP Recognize the SOJ-6 Cell Surface
We next determined whether antibodies to FAPP were
able to recognize the surface of SOJ-6 cells. For this
purpose, these cells were cultured to subconfluence on
coverslips and incubated with primary antibodies and then
with the corresponding FITC-labeled secondary antibodies.
As shown in Figure 2 (panel A), antigenic sites recognized
by pAbL64 and two monoclonal antibodies mAbJ28 and
mAb16D10 directed against the C-terminal domain of FAPP
[22] (unpublished results) decorated the plasma membrane
of the SOJ-6 cells (Figure 2, panels A2–A4). The polyclonal
antibodies, pAbAntipeptide, obtained from a peptide se-
quence of FAPP located within the N-terminal domain of
the protein poorly reacted with SOJ-6 plasma membranes
(Figure 2, panel A5). In control experiments omitting either
primary antibodies, no significant labeling of cell membranes
was obtained (Figure 2, panel A1). These results were
confirmed by fluorescence-activated cell sorter (FACS) anal-
yses (Figure 2, panel B). Ten to 100 times more fluorescence
than control was associated with cells probed with pAbL64,
mAbJ28, and mAb16D10. A low fluorescence, albeit higher
than that of control, was associated with cells incubated with
the pAbAntipeptide. These results show that antibodies to
the C-terminal domain of FAPP bound to structures that were
present at SOJ-6 cell surface.
Antibodies to FAPP Recognize a 32-kDa Surface Peptide
We next determined whether surface antigenic structures
detected by antibodies to FAPP were associated with the
120-kDa protein or with 28- to 32-kDa peptides. For this
purpose, SOJ-6 cells were grown until confluence, then
membrane proteins and peptides were biotinylated, and cells
were ultimately lysed. Biotinylated membrane proteins and
peptides were further purified on steptavidin–agarose
beads. The material eluted by acetic acid was separated
on SDS-PAGE and electrotransferred onto nitrocellulose
membranes. Membranes were finally probed with antibod-
ies. We showed that many proteins were reactive to anti-
bodies to biotin (Figure 3, lane 1; 0.5 mg of protein loaded),
but only one peptide of 32 kDa was probed with pAbL64
(Figure 3, lane 2; 5 mg of protein loaded), mAbJ28 (Figure 3,
lane 3; 5 mg of protein loaded), and mAb16D10 (Figure 3,
lane 4; 5 mg of protein loaded). Furthermore, antibodies to
an N-terminal sequence of FAPP (pAbAntipeptide) did react
neither with this 32-kDa peptide nor with any other biotin-
ylated material (Figure 3, lane 5). The presence of the glu-
cose transporter Glut-1 migrating as the mature membrane
form of the protein [34] suggested that this material is repre-
sentative of membrane proteins (Figure 3, lane 6). Taken
as a whole, those results demonstrated that antibodies to
the C-terminal domain of FAPP recognized antigenic struc-
tures present at the plasma membrane of human tumoral
pancreatic SOJ-6 cells. These antigenic structures are asso-
ciated with a 32-kDa peptide.
Figure 1. Immunodetection of proteins present in extracellular medium and
cell lysate of SOJ-6 cells. Subconfluent SOJ-6 cells were cultured in Opti-
MEM medium for 24 hours. Then the cell culture medium was withdrawn and
the cells were harvested, lysed, and centrifuged to eliminate insoluble
materials. Proteins present in the soluble fraction were separated on SDS-
PAGE and electrotransferred onto nitrocellulose membranes. The mem-
branes were finally probed with the polyclonal antibody to BSDL, pAbL64, in
cell culture medium (lane 1) and in the soluble fraction of cell lysate (lane 2).
Arrows indicate the apparent molecular mass of detected proteins or
peptides.
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Polyclonal and Monoclonal Antibodies to FAPP Recognize
the Same 32-kDa Peptide
From this point, it was essential to determine whether
antigenic structures recognized by polyclonal and monoclo-
nal antibodies to FAPPwere carried out by the same peptide.
To solve this, we have first purified biotinylated surface
peptides by streptavidin–agarose as described in the Mate-
rials and Methods section. Secondly, we have isolated bio-
tinylated peptides reactive to pAbL64 and to mAbJ28 by
means of affinity chromatography on respective agarose-
immobilized antibodies column, then the material eluted from
each immobilized antibodies column was separated on SDS-
PAGE and electrotransferred onto nitrocellulose mem-
branes. Membranes were then probed with the counterpart
antibodies. As shown in Figure 4A, the material eluted from
the immobilized pAbL64 affinity column was reactive on
Figure 2. SOJ-6 surface reactivity with antibodies to FAPP. Panel A: Subconfluent SOJ-6 cells were fixed with paraformaldehyde (3%) then probed with different
antibodies pAbL64 (lane 2), mAbJ28 (lane 3) mAb16D10 (lane 4), and pAbAntipeptide (lane 5) before immunofluorescence microscopy analyses. Lane 1 shows
the nonspecific binding of secondary FITC-labeled antibody. Panel B: Cell surface antigen expression was analyzed by flow cytometry using pAbL64 (lane 2),
mAbJ28 (lane 3), mAb16D10 (lane 4), and pAbAntipeptide (lane 5) and compared to controls (lane 1), which shows the nonspecific binding of secondary FITC-
labeled antibodies.
Figure 3. Immunodetection of biotinylated cell surface antigens in SOJ-6
cells. SOJ-6 cells were grown until confluence, and membrane proteins and
peptides were biotinylated and lysed. Then biotinylated membrane proteins
were purified on streptavidin–agarose affinity column. The material eluted
with 0.1 M acetic acid was separated on SDS-PAGE and electrotransferred
onto nitrocellulose membranes, which were finally probed with antibodies:
antibiotin (lane 1; 0.5 g of protein), pAbL64 (lane 2; 5 g of protein), mAbJ28
(lane 3; 5 g of protein), mAb16D10 (lane 4; 5 g of protein), pAbAntipeptide
(lane 5; 5 g of protein), and antibodies to Glut-1 (lane 5; 5 g of protein).
Arrow indicates the apparent molecular mass of detected peptides.
Figure 4. Immunodetection of biotinylated cell surface antigens purified on
agarose-immobilized antibodies to FAPP. Membrane peptides of SOJ-6 cells
were first biotinylated and purified on streptavidin –agarose affinity column
(Figure 3). (A) The material eluted with acetic acid was purified on agarose-
immobilized pAbL64 affinity column and the material eluted was separated on
SDS-PAGE and electrotransferred onto nitrocellulose membranes. Then
membranes were probed with mAbJ28. (B) Conversely, the material eluted
with acetic acid was purified on agarose-immobilized mAbJ28 affinity column
and the material eluted was separated on SDS-PAGE and electrotransferred
onto nitrocellulose membranes. Then membranes were probed with pAbL64.
The detection of immunoprecipitated biotinylated peptides was performed
using Lumi-Light plus Western Blotting kit. Arrow indicates the apparent
molecular mass of detected peptide.
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Western blot analysis with the mAbJ28. Of course, the
material eluted from the agarose-immobilized mAbJ28 was
also recognized by pAbL64 (Figure 4B). In each case, a 32-
kDa peptide was detected following affinity column and
Western blot analysis. Therefore, the same peptide was
recognized by polyclonal antibodies to FAPP and mAbJ28,
a monoclonal antibody that binds specifically to a glycotope
present on the C-terminal domain of FAPP [22].
Geldanamycin Increases the Amount of Peptides Presented
at the Cell Surface
In a recent report, we showed that the 94-kDa glucose-
regulated protein or Grp94 assisted the sorting of the BSDL,
and that the fraction of the protein that cannot be folded by
Grp94 was addressed to a degradative compartment impli-
cating the proteasome [26]. We further showed that gelda-
namycin, a drug that impaired the interaction of Grp94 with
its substrate, decreased the secretion of BSDL and en-
hanced the amount of ubiquitinylated BSDL that was further
addressed to the proteasomal degradation [7]. Therefore, we
reasoned that if the 32-kDa peptide that was presented at the
surface of pancreatic tumoral SOJ-6 cells is actually the end
product of the degradation of FAPP, geldanamycin should
increase the amount of the 32-kDa peptide, which is in fine
presented at the cell surface. To verify this point, SOJ-6 cells
were cultured to subconfluence then the medium was
replaced with fresh medium supplemented or not with gelda-
namycin (3 mM) and further incubated for 6 hours. At the end
of the incubation period, the culture medium was withdrawn
and cells were washed, harvested, and lysed. Compared to
control cells incubated in the absence of geldanamycin, the
secretion of FAPP was decreased by approximately 70%,
independently of the way to record the protein [i.e., either by
quantification of Western blot using pAbL64 (Figure 5, A and
B) or by determination of FAPP activity (Figure 5C)]. These
results agreed with those already found using the rat pan-
creatic AR4-2J cell line [7]. In another set of experiments,
SOJ-6 cells, either treated with geldanamycin under above-
described conditions or mock-treated, were harvested using
a nonenzymatic cell dissociation solution for extracellular
FACS staining and trypsin–EDTA solution for intracellular
FACS staining. As shown in Table 2, the amount of antigenic
structures presented at the surface of SOJ-6 cells and
recognized by the pAbAntipeptide was not increased by
geldanamycin when compared to control cells. However,
the presentation of antigenic structures recognized by mono-
clonal antibodies mAbJ28 and mAb16D10 to the C-terminal
domain of FAPP was significantly increased by 42% and
101%, respectively. Conversely, intracellular FACS staining
(Table 2) showed that the antigenic structures recognized by
monoclonal antibodies mAb16D10 to the C-terminal domain
of FAPP were significantly decreased by 42%, whereas the
structures recognized by the pAbAntipeptide are only slightly
modified. These results suggested that the presentation of
the 32-kDa peptide at the plasma membrane of SOJ-6 cells
is increased under conditions promoting the dissociation of
Grp94/FAPP complexes by geldanamycin [7]. Therefore, the
32-kDa peptide presented at the tumoral cell surface is
probably the C-terminal domain of FAPP, which could be
the end product of the intracellular degradation of this latter
protein.
The 32-kDa Peptide Is the C-terminal Domain of FAPP
As suggested above by antibody reactivity, the 32-kDa
peptide could be representative of the C-terminal domain of
FAPP. On FAPP, this domain is composed of six identical
repeated sequences of 11 amino acids, whereas on BSDL, it
is formed by 16 of these identical repeated sequences. A
survey of the literature suggested that classic trypsin-like,
Figure 5. Effect of geldanamycin on the rate of FAPP secretion by SOJ-6
cells. Subconfluent SOJ-6 cells were incubated in fresh RPMI in the absence
(empty column) or presence (dashed column) of 3 M geldanamycin and
further incubated for 6 hours. At the end of incubation, the culture medium
was removed. The secretion of FAPP was analyzed by SDS-PAGE and
Western blot analysis using pAbL64 (A), and the quantification of this
Western blot analysis is performed by the NIH Program (B). The FAPP activity
was also determined (C) using 4-nitrophenyl hexanoate as substrate. This
experiment was done in triplicate and results are presented as mean ± SD.
Glycotope of FAPP in Pancreatic Cancer Cells Panicot-Dubois et al. 719
Neoplasia . Vol. 6, No. 6, 2004
chymotrypsin-like, and peptidyl glutamyl-peptide–hydrolyz-
ing activities of the proteasome [35] can degrade N-glycosyl-
ated FAPP and BSDL [26,36], leaving undegraded the
C-terminal repeated sequences. Cytosolic ubiquitous cal-
pain activities [37] that promote restricted cleavages of pro-
teins [38,39] might also leave repeated sequences intact.
Although these repeated sequences have built-in PEST
degradation signals [40], they can further be protected from
intracellular proteolysis by their high O-glycosylation
[21,22]. The N-terminal domain of FAPP and that of BSDL
are sensitive to proteolysis by either proteasome or calpains,
and by any other proteases such as endoproteinase Lys-C
(unpublished observations). Therefore, FAPP obtained from
the serum-free culture medium of SOJ-6 cells and BSDL
isolated from human pancreatic juice were treated with
endoproteinase Lys-C, overnight at 37jC, then analyzed
on SDS-PAGE and Western blot analysis using pAbL64,
mAbJ28, and mAb16D10 to detect any antigenic structure
generated by the proteolysis. As shown in Figure 6A, the
mock-treated FAPP (lane 2) was a little degraded compared
to untreated (i.e., without incubation overnight at 37jC)
FAPP (lane 1), likely by proteases cosecreted along with
FAPP by SOJ-6 cells. However, FAPP (six C-terminal re-
peated identical sequences) treated with endoproteinase
Lys-C (lanes 3 and 4) generated many peptides, among
which the one associated with an Mr of 32 kDa was reactive
with pAbL64 (lane 3),mAbJ28 (lane 4), andmAb16D10 (lane
5). Following the same treatment, pure human pancreatic
BSDL (Figure 6B) gave peptides with a lower migration
(around 50–60 kDa) due to the presence of 16 repeated
Table 2. Cell Expression of Antigenic Structures on SOJ-6 Cell Line after Geldanamycin Treatment.
Antigen Cell Surface Expression Intracellular Expression
Control Geldanamycin (3 mM) Variation* (%) Control Geldanamycin (3 mM) Variation* (%)
Median Fluorescence Intensityy Median Fluorescence Intensityy
mAbJ28 8.3 11.8 +42 7.7 7.3 5
mAb16D10 36.9 74.4 +101 81.8 47.3 42
pAbAntipeptide 5.1 5.1 0 3.2 3.7 15
*Percentage of variation versus control; average of two independent experiments.
yMedian fluorescence intensity of cells stained with the respective antibodies as determined by FACScan analysis.
Figure 6. Endoproteinase Lys-C treatment of BSDL, secreted FAPP, and recombinant C-terminal peptide of FAPP. (A) FAPP obtained from the serum-free culture
medium of SOJ-6 cells was treated (+) or mock-treated () with endoproteinase Lys-C (2% by weight), overnight at 37C, then analyzed on SDS-PAGE and
Western blot analysis using pAbL64. Lane 1 represents untreated FAPP present in the SOJ-6 cell culture medium. Lane 2 represents mock-treated FAPP of the
SOJ-6 cell culture medium. Lane 3 represents FAPP of the SOJ-6 cell culture medium treated with endoproteinase Lys-C. Lanes 4 and 5 represent FAPP of the
SOJ-6 cell culture medium treated with endoproteinase Lys-C and immunodetection using mAbJ28 and mAb16D10, respectively. (B) Pure human pancreatic BSDL
was treated and analyzed under identical conditions. Lane 1 represents native BSDL, lane 2 represents mock-treated BSDL, and lane 3 represents BSDL treated
with endoproteinase Lys-C. Lane 4 represents BSDL treated with endoproteinase Lys-C and immunodetection using mAbJ28. (C) The recombinant C-terminal
peptide of FAPP obtained from CHO-C2-F3 cells transfected with the pSecCterFAPP was treated (+) or mocked-treated () with endoproteinase Lys-C, overnight
at 37jC, then analyzed on SDS-PAGE and Western blot analysis using pAbL64. Lane 1 represents recombinant C-terminal peptide, lane 2 represents mock-
treated recombinant C-terminal peptide, and lane 3 represents recombinant C-terminal peptide treated with endoproteinase Lys-C. Lanes 4 and 5 represent
recombinant C-terminal peptide treated with endoproteinase Lys-C and immunodetection using mAbJ28 and mAb16D10, respectively. Arrows indicate the
apparent molecular mass of detected peptides.
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sequences and, overall, no peptide associated with a 32-kDa
size and no material reactive withmAbJ28were detected. To
confirm that the 32-kDa peptide corresponded to tandemly
repeated C-terminal sequences of FAPP, the sequence
encoding this domain has been cloned and inserted into an
eukaryotic vector named pSecCterFAPP. This vector allows
the expression and secretion of the translated product. CHO-
C2-F3 cells equipped with glycosyltransferases essential for
the establishment of the J28 epitopic structure were trans-
fected with the pSecCterFAPP vector and selected as al-
ready described [23]. Cells were cultured in Opti-MEM
medium and allowed to secrete a translation product of
approximately 42 kDa (Figure 6C, lanes 1 and 2), which
arborated the J28 epitope [23]. Once treated with endopro-
teinase Lys-C, this product generated a 32-kDa peptide that
was recognized by pAbL64 (Figure 6C, lane 3), mAbJ28
(Figure 6C, lane 4), and mAb16D10 (Figure 6C, lane 5).
Finally, the 32-kDa surface peptide was sequenced to
demonstrate that it is actually issued from FAPP degrada-
tion. For this purpose, SOJ-6 cell surface proteins were
biotinylated and biotin-labeled material was further purified
on steptavidin–agarose beads. The material eluted from
beads was freeze-dried and treated for SDS-PAGE. The
gel area corresponding to pAbL64-reactive material was
excised, electroeluted, and sequenced. The N-terminal se-
quence of this peptide was Thr–Gly–Asp–Pro and corre-
sponded to residues 474 to 477 of FAPP located some
100 residues to the first tandemly C-terminal repeated se-
quence of FAPP [17]. Therefore, we must conclude that
the 32-kDa peptide reactive to pAbL64 and mAbJ28
and presented at the SOJ-6 cell surface corresponds to the
C-terminal mucin-like domain of FAPP consecutive to its
intracellular degradation.
mAb to C-terminal Domain of FAPP Decreases the Growth
Rate of Inoculated SOJ-6 Pancreatic Tumoral Cells
At that point, our results indicate that pancreatic tumoral
cells SOJ-6 expressed at their surface the 32-kDa C-terminal
peptide of the FAPP. Because BSDL is not expressed in
tumoral cell lines [18], targeting the C-terminal domain of the
FAPP using specific antibodies could be an interesting
strategy in vivo to diminish the growth of the pancreatic
tumor. Therefore, the efficacy of the monoclonal antibody
mAb16D10 against SOJ-6 tumors has been examined in
preventative xenograft model using nude mice. For this
purpose, a prospective study was performed andmAb16D10
or PBS vehicle was administered intraperitoneally on the day
before tumor cell inoculation in the flank of each animal and
was given three times per week for 2 weeks. At a dose of
0.5 mg per injection (assay group), mAb16D10 largely
decreases the growth of xenografted SOJ-6 cells (Figure 7).
The rate of tumor growth in the assay group stays very low
for a period up to 10 weeks. At this time, the range of tumor
volume was 0.62 to 3.45 cm3 (mean volume 1.59 ± 0.55 cm3,
n = 5) for the control group (vehicle), which is higher than the
tumor size range in the assay group (0.5 mg per injection;
i.e., 0–0.76 cm3; mean volume 0.41 ± 0.,15 cm3). To
determine whether the antibody blocks tumor cell prolifera-
tion, we have recorded in vitro the proliferation of SOJ-6 cells
by [3H]thymidine incorporation. Our results indicate that the
SOJ-6 cell proliferation was not modified by the presence of
mAb16D10 at 0.5 mg/ml (data not shown), suggesting that,
in vivo, the antibody may not affect directly SOJ-6 cells
proliferation in the tumor. In conclusion, mAb16D10 binds
to the C-terminal domain of FAPP presented at the surface of
SOJ-6 cells and decreases the rate of growth of xenografted
pancreatic tumor.
Discussion
In the last decade, the incidence of cancers of the exocrine
pancreas has been increasing [41]. Despite advances in the
treatment of gastrointestinal malignancies, no significant
progress has been made against pancreatic cancer, al-
though chemotherapy associated with radiotherapy has
some positive effects on the survival of patients [42]. The
curative resectability rate is very low because the cancer is
asymptomatic and its diagnosis in most patients occurs once
the tumor has spread into lymph nodes or has formed distant
metastases [43]. Consequently, exocrine pancreatic cancer
still represents a virtual death sentence for the patient and
new therapies are promising. Specific markers to target
pancreatic tumoral cells are spare, albeit many monoclonal
antibodies were generated against malignant pancreatic
epithelial cells. These include Span-1 [44], Du-Pan-2 [45],
CA19-9 [46], CA50 [47], and CAR-3 [48]. These antibodies
generally displayed distinct patterns of tissue staining, often
being more highly expressed in certain tissues and tumors
than others. However, the reactivity of these antibodies
depends upon the genotype of patients [49,50].
FAPP is an oncofetal glycovariant of the BSDL [16], a
lipolytic enzyme secreted as a component of the pancreatic
juice and involved in the duodenal hydrolysis of cholesterol
Figure 7. Antitumor effect of mAb16D10 on SOJ-6 xenograft growth rates in
a preventative model. SOJ-6 cells were injected subcutaneously into the right
flank of 6-week-old nude mice (n = 5) at day 0. Mice were injected
intraperitoneally with 0.5 mg of mAb16D10 (assay group, triangle) or with
PBS vehicle only (control group, diamond) starting 1 day prior to tumor cell
inoculation. Data are expressed as mean tumor volume ± SEM.
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esters [2]. FAPP is a specific constituent of pancreatic acinar
cells, which are associated with the ontogenesis and devel-
opment of the human pancreas. The protein is defined as a
member of the oncodevelopment-associated pancreatic
antigens, the earliest expression of which is seen in undif-
ferentiated mesenchymal cells and nascent acini. This ex-
pression is concomitant to the beginning of the morphologic
differentiation of the pancreas, which occurs after 9 to 10
weeks of gestation [15]. Maximal synthesis of FAPP appears
at the time of intense acinar cell proliferation, between 15
and 25 weeks gestation. Then the expression of FAPP
declines progressively to reach a very low level in adults
[15]. FAPP has never been detected in any other fetal tissues
[15] and in any adult tissues, except the pancreas of patients
suffering from cancer [14]. FAPP was first identified using
polyclonal antiserum and further characterized in human
pancreas withmAbJ28 [14]. The reactivity of this monoclonal
antibody with serum is significantly increased in pancreatic
adenocarcinoma, and mAbJ28 recognized a structure found
in human tumoral pancreas and human pancreatic tumor cell
lines, SOJ-6 and BxPC-3 [18,51], but not in normal tissues
[14]. Furthermore, it has been shown that mAbJ28 recog-
nizes a carbohydrate antigenic structure [13,22] located
within O-glycosylated mucin-like C-terminal domains of
FAPP [16,22,23].
Many works suggested that epitopic structures recog-
nized by monoclonal antibodies to FAPP are present at the
surface of tumoral pancreatic cells. These studies included
immunocytologic localization of FAPP within human pancre-
atic tumoral tissues compared to normal tissues [14], and the
specific targeting of nitrosamine-induced pancreatic tumor in
hamsters (which expressed the J28 epitope) with the radio-
labeled mAbJ28 [27]. Furthermore, in diabetic patients,
specific antibodies to the C-terminal domain of BSDL were
found in the blood circulation, suggesting that this domain
could be presented at the surface of pancreatic cells under
inflammatory or pathologic conditions [24] to activate the
immune system.
In this paper, we showed that two monoclonal antibodies
mAbJ28 andmAb16D10 directed against theO-glycosylated
C-terminal domain of FAPP recognized structures present at
the surface of human pancreatic tumoral SOJ-6 cells. We
further demonstrated that these epitopic structures are car-
ried out by a 32-kDa peptide located at the surface of SOJ-6
cells and that this peptide corresponded to the O-glycosyl-
ated repeated sequences of FAPP as it is demonstrated by:
1) the reactivity of mAbJ28, which recognized fucosylated
O-glycan structures linked to the C-terminal domain of FAPP
[22,23]; 2) FAPP and its recombinant C-terminal domain
expressed by CHO-C2-F3 cells equipped with glycosyltrans-
ferases involved in the formation of the J28 epitope [23],
which is generated upon proteolysis of a peptide with an
electrophoretic migration identical to that of the peptide
detected at the cell membrane level. Under identical con-
ditions, BSDL leads to a 50- to 60-kDa peptide; 3) geldana-
mycin, a drug that impaired the folding of the normal
glycovariant of FAPP and addressed the protein toward the
proteasome degradation [7], which enhanced the reactivity
of tumoral cell membranes with mAbJ28 and mAb16D10; 4)
polyclonal antibodies directed against an N-terminal peptidic
sequence of FAPP located outside repeated sequences
(pAbAntipeptide), which were ineffective in membrane-bind-
ing studies and Western blot analysis of biotinylated mem-
brane proteins; and 5) finally, the N-terminal sequence of the
SOJ-6 cell surface peptide, which corresponded to that of a
sequence starting at Thr474 of the FAPP sequence and
located just before repeated sequences of the C-terminal
domain of the protein [17].
How the C-terminal peptide of FAPP constituted of
O-glycosylated tandemly repeated sequences is presented
at the surface of tumoral pancreatic cells is an open question.
The Grp94, which plays a pivotal role in the secretion of the
normal variant of FAPP [5,7], has gained attention for its
ability to elicit CD8+ cytotoxic T-cell responses to its bound
peptide [52]. A minor fraction of Grp94 localizes to the cell
surface, albeit a built-in canonical endoplasmic reticulum
retention signal is present on Grp94 [53]. Interestingly, this
altered localization has, for instance, only been seen in
transformed cells [52]. The presentation of peptides to the
immune system by oligomers of Grp94 [54] explains the
tumor rejection activity of Grp94 [55], which is mediated by
means of CD8+ T-cell cytotoxic response [56]. However,
data obtained with geldanamycin seem a priori to disagree
with the involvement of Grp94 in the presentation to the cell
surface of the C-terminal domain of FAPP. Furthermore, the
size of this peptide does not correlate with that of peptides
usually presented to the cell surface through major histo-
compatibility complexes [57]. More investigations will be
necessary to elucidate this mechanism. The oncodevelop-
mental self-character of FAPP might have led to immuno-
logic tolerance and no circulating antibodies to FAPP were
detected in the blood of patients suffering from pancreatic
carcinoma [24]. It is also possible that T cells reactive to the
pancreatic tumor may be present at insufficient level, do not
have enough avidity for tumor cells, or do not produce the
appropriate cytokines to mediate the destruction of the
tumor. The tumor itself may also actively participate in
immune suppression [58]. All these mechanisms may limit
the effectiveness of natural immune responses against tu-
moral cells. The achievements of active immunization
against infectious diseases have provided hope that cancer
patients could be actively immunized against their own
cancers to prevent or treat the disease. New approaches in
the development of cancer vaccines require the identification
of human cancer antigens. But these approaches are limited
by minute quantities of cancer antigenic molecules present
at the surface of tumoral cells. New findings presented in this
study demonstrate the presence of specific antigens, origi-
nating from intracellular degradation of FAPP, at the surface
of pancreatic tumoral SOJ-6 cells. The possibility to obtain
recombinant structures reactive with monoclonal antibodies
toO-glycan structures of the C-terminal repeated sequences
of FAPP [23,24] may be promising tools in active immuno-
therapy of pancreatic cancers. However, antibodies to these
structures may be interesting therapeutic agents for passive
immunization as described with Herceptin, a monoclonal
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antibody against the tyrosine kinase receptor HER-2 and
breast cancer [59]. The prospective study as presented here
suggests that mAb16D10 has in vivo a preventative anti-
tumor activity against SOJ-6 cells expressing the C-terminal
domain of FAPP at their surface. Intraperitoneal injections of
mAb16D10 in mice xenografted with human pancreatic
tumoral SOJ-6 cells decreased the growth rate of the tumor.
This may have resulted from the recognition of C-terminal
peptide of FAPP at the surface of tumoral SOJ-6 cells by
mAb16D10 followed by a possible activation of complement
cascade and/or macrophage-mediated cytotoxicity. Further
studies will be necessary to confirm these data and to
understand the mechanism by which mAb16D10 inhibits
pancreatic tumor growth. Furthermore, the unique specificity
of mAb16D10, which recognizes SOJ-6 cell membrane anti-
gens and also binds to pancreatic adenocarcinomatous
tissues but not to normal pancreatic tissues (some studies
are in progress), could be effective in passive immunologic
therapy of exocrine pancreatic tumors.
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